LivaNova PLC filings document the regulatory disclosures of an England and Wales public limited company with ordinary shares listed on Nasdaq under LIVN. Its Form 8-K reports primarily cover operating and financial results, earnings releases, business update calls, material events, and governance changes involving senior officers.
Proxy materials describe annual general meeting procedures, shareholder voting matters, director and governance proposals, and the company’s ordinary share structure. The filings also provide formal records for capital-structure disclosures and corporate governance matters relevant to LivaNova’s medical technology operations in neurological and cardiac conditions.
LivaNova PLC Chief Financial Officer Alex Shvartsburg sold 2,500 ordinary shares on November 12, 2026, at $90.91 per share. The sale was made under a Rule 10b5-1 plan adopted on August 10, 2026. He directly held 42,147 ordinary shares following the transaction.
LivaNova PLC officer Alex Shvartsburg filed notice of an intended sale of 2,500 common shares, with an approximate sale date of November 12, 2026. The notice lists an aggregate market value of $227,275 and Merrill Lynch as the broker. It lists August 10, 2026 as the date of plan adoption or giving of instructions if relying on Rule 10b5-1.
LivaNova PLC (LIVN) is the issuer of common stock for which Invesco Ltd., as a parent holding company to its investment advisers, may be deemed to beneficially own 2,928,425 shares, or 5.3% of the class. Invesco Ltd. reports sole voting power over 2,913,963 shares and sole dispositive power over 2,928,425 shares, with zero shared voting or dispositive power. The shares are held of record by Invesco Ltd.’s clients, who have the rights to dividends and sale proceeds; no one person has greater than 5% economic ownership in the reported securities.
LivaNova PLC (LIVN) common stock is reported as beneficially owned by FMR LLC in the amount of 3,897,919.56 shares, equal to 7.1%, as of September 30, 2026. Abigail P. Johnson is also listed with beneficial ownership of 3,897,919.56 shares and 7.1%.
FMR LLC reports sole voting power over 3,896,804.85 shares and sole dispositive power over 3,897,919.56 shares. Abigail P. Johnson reports no sole or shared voting power and sole dispositive power over 3,897,919.56 shares.
LivaNova PLC reported third-quarter 2026 revenue of $393.148 million, up 9.9% from $357.753 million; nine-month revenue was $1,145.993 million, up 11.6%. Third-quarter net income was $34.294 million versus $26.784 million. Nine-month net income was $165.157 million, compared with a $273.377 million loss a year earlier. The 2026 nine-month result included a $95.0 million discrete Italian tax benefit; the 2025 period included $363.8 million of SNIA environmental liability expense.
Both segments recorded higher quarterly revenue: Cardiopulmonary $225.304 million, up 10.9%, and Neuromodulation $166.127 million, up 11.1%. Cardiopulmonary segment income fell to $7.578 million from $24.698 million, while Neuromodulation segment income rose to $62.134 million from $56.185 million. Consolidated operating income was $28.425 million, down from $54.012 million, and operating cash flow for nine months was $155.467 million versus $171.943 million. Cash and cash equivalents were $563.467 million as of September 30, 2026.
LivaNova PLC reported third-quarter 2026 revenue of $393.1 million, up 9.9% reported and 10.0% on a constant-currency basis from a year earlier. Cardiopulmonary revenue was $225.3 million, up 10.9%, and Neuromodulation revenue was $166.1 million, up 11.1%. U.S. GAAP operating income was $28.4 million versus $54.0 million; net income was $34.3 million versus $26.8 million. Diluted EPS was $0.11 versus $0.49, while adjusted diluted EPS was $1.23 versus $1.11. Third-quarter operating cash flow was $73.7 million and adjusted free cash flow was $55.8 million.
LivaNova raised full-year 2026 revenue growth guidance to 9%–10% on a constant-currency basis and adjusted diluted EPS guidance to $4.40–$4.50; adjusted free cash flow guidance remained $140 million to $160 million. The company said its new oxygenator manufacturing line began operational production. In October 2026, the AMA CPT Editorial Panel announced Category I CPT codes including LivaNova’s proximal hypoglossal nerve stimulation therapy, with an expected effective date of January 1, 2028. LivaNova also reported 36-month CORE-VNS study results showing a 76% median reduction in seizure frequency.
LivaNova PLC (symbol: LIVN) is the issuer of record for a Form 4 filing submitted to the SEC. Liddy Anne M. reported acquisition or exercise transactions in this Form 4 filing.
LivaNova PLC (LIVN) reported that Chief Legal Officer Anne M. Liddy received a grant of 6,291 Restricted Stock Units (RSUs) on September 15, 2026 under the Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan. The RSUs vest 20% on March 30, 2027 (pro‑rated from the grant date), 40% on March 30, 2028, and 40% on March 30, 2029, and are subject to forfeiture before vesting. Each RSU represents a contingent right to receive one ordinary share of LivaNova PLC.
LivaNova PLC (LIVN) director Francesco Bianchi reported selling 3,500 Ordinary Shares on September 10, 2026 in an open-market transaction at a weighted-average price of $78.0092 per share, with individual sale prices ranging from $77.97 to $78.04. After this sale, he directly holds 4,434 Ordinary Shares, and no Rule 10b5-1 trading plan is reported for this transaction.
LivaNova PLC (LIVN) received a notice that officer Francesco Bianchi intends to sell up to 3,500 shares of Common Stock under Rule 144. The shares relate to a vesting of a restricted stock unit award on June 15, 2026, granted as part of the issuer’s equity compensation plan.
The planned sale is to be executed through Merrill Lynch, with an aggregate market value noted as $273,032.19 and 55,093,507 shares shown in the same line as contextual share data. The filing also lists Bianchi’s prior Common Stock sales during the past three months.